Determinants of the HbA1c-lowering effect of sitagliptin when added to ongoing insulin therapy in Japanese patients with type 2 diabetes
- 183 Downloads
This study assessed the independent predictors of the HbA1c-lowering effect of sitagliptin when added to ongoing insulin therapy in Japanese patients with type 2 diabetes.
Data were retrieved from the medical records of 179 patients with type 2 diabetes on stable-dose insulin alone or stable-dose insulin and oral hypoglycemic agents who received sitagliptin (25 or 50 mg) added on once daily for inadequate glycemic control for at least 12 weeks. Spearman’s rank correlation coefficient analysis was performed to assess the correlations of two independent continuous variables. Multiple stepwise regression analysis was used to search for independent predictors of reduction in HbA1c levels after 12 weeks of sitagliptin add-on treatment (ΔHbA1c).
Among all subjects, ΔHbA1c was significantly correlated with baseline HbA1c alone (r = 0.410, P < 0.0001). However, multiple stepwise regression analysis using baseline variables revealed that the three independent factors contributing to ΔHbA1c were baseline HbA1c (r2 = 0.16, P < 0.0001), total daily insulin dose (r2 = 0.05, P = 0.002), and diabetes duration (r2 = 0.03, P = 0.006).
The results suggest that an increased total daily insulin dose and prolonged diabetes duration contribute in part to the attenuation of the HbA1c-lowering effect of sitagliptin added to ongoing insulin therapy in Japanese patients with type 2 diabetes. A prospective analysis of a larger population with a longer study duration is warranted to confirm these findings.
KeywordsHbA1c Sitagliptin Insulin Type 2 diabetes
Conflict of interest
None of the authors have any conflicts of interest to declare.
- 1.Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281:2005–12.PubMedCrossRefGoogle Scholar
- 2.Hermansen K, Davies M, Derezinski T, Martinez RG, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care. 2006;29:1269–74.PubMedCrossRefGoogle Scholar
- 6.Kennedy L, Herman WH, Strange P, Harris A. Impact of active versus usual algorithmic titration of basal insulin and point-of-care versus laboratory measurement of HbA1c on glycemic control in patients with type 2 diabetes: the Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1C) trial. Diabetes Care. 2006;29:1–8.PubMedCrossRefGoogle Scholar
- 16.Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther. 2005;78:675–88.PubMedCrossRefGoogle Scholar
- 32.Senmaru T, Fukui M, Kobayashi K, Iwase H, Inada S, Okada H, et al. Dipeptidyl peptidase IV inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrations. J Diabetes Invest. 2012; doi:10.1111/j.2040-1124.2012.00220.x.